Skip to content

Study for establishing evaluation method of bone marrow MSC mobilizer KOI2 activity

Study for establishing evaluation method of bone marrow MSC mobilizer KOI2 activity - KOI2 activity study in human

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018576
Enrollment
40
Registered
2015-08-06
Start date
2015-08-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Group1:KOI2 0.15mg/kg or Placebo, single dose administration Group2:KOI2 0.5mg/kg or Placebo, single dose administration Group3:KOI2 1.5mg/kg or Placebo, single dose administration Group4:KOI2 3

Sponsors

Osaka University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Healthy Japanese male age >=20 years and<= 40 years old "2) BMI (kg/m2) more than 18.0 and less than 25.0 BMI = weight [kg] / (height [m]) 2" 3) A subject who hans not been smoking form more than 1 year and can agree to stop smoking from the day before the first dosage adminiatraion through post administration clinical visits 4) A subject who agrees to not consume alcohol 24 hours before hospitalization till discharge and 24 hours prior to every post clinical visits 5) A subject who agrees to prevent pregnacy until 28 days post the last dosage administration

Exclusion criteria

Exclusion criteria: 1) A subject who has liver, kidney, GI, respiratory, heart and a blood system disease 2) A subject who has a past histroy of drug dependency 3) A subject who is difficult for intravenous administration (including episodes of vagal reflex syncope) 4) A subject who has the past of clinically significant drug allergy symptom and allergy to vaccine (anaphylactic shock, severe food allergy, hives, recurrent dermatitis, drug hypersensitivity, allergy to protein preparation, vascular edema) 5) A subject who has clinically important abnormal laboratory data by a blood test or urine test at the time of screening 6) A subject who is HIV Ab, HBs Ag, or HCV Ab positive by screening examination 7) Screening or baseline Qtc is over 450 msec or QRS interval is over 120 msec by 12-lead electrocardiogram

Design outcomes

Primary

MeasureTime frame
Number of MSCs in peripheral blood

Secondary

MeasureTime frame
Differential blood cell count

Countries

Japan

Contacts

Public ContactKatsuto Tamai

Osaka University Hospital Dermatology

tamai@gts.med.osaka-u.ac.jp06-6210-8396

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026